AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease.